Overview Financials News + Filings Key Docs Charts Ownership
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
|
|
TRINITY BIOTECH PLC (TRIB)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/10/2023 |
6-K
| Quarterly results |
| 10/06/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 07/10/2023 |
6-K
| Quarterly results |
| 05/08/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 05/01/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 04/25/2023 |
6-K
| Quarterly results |
| 04/24/2023 |
6-K
| Quarterly results |
| 03/27/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 03/27/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 02/22/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"6-K",
"Amended and Restated Credit Agreement and Guaranty dated as of among Trinity Biotech, Inc., Fitzgerald Industries International, Inc., Clark Laboratories, Inc. ), Biopool U.S., Inc. ,",
"Exhibit 4.12.1 First Amendment to Warrant Certificate This First Amendment to Warrant Certificate, dated as of February 21, 2023 , is entered into by and among Trinity Biotech PLC, a public limited company organized and existing under the laws of Ireland and Perceptive Credit Holdings III, LP, a Delaware limited partnership . Recitals Whereas, the Company issued to the Holder that certain Warrant To Purchase American Depositary Shares represented by American Depositary Receipts, dated as of January 27, 2022, . Capitalized terms used herein but not otherwise defined herein shall have the meanings ascribed thereto in the Warrant. Whereas, in connection with that certain Amended and Restated Credit Agreement and Guaranty, dated as of February 21, 2023 , by and among Trinity Biotech, Inc., a D...",
"[email protected]" |
|
| 01/10/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 12/16/2022 |
6-K
| Quarterly results |
| 12/09/2022 |
6-K
| Quarterly results |
| 11/15/2022 |
6-K
| Quarterly results |
| 11/04/2022 |
6-K
| Quarterly results |
| 11/04/2022 |
6-K
| Quarterly results |
| 11/02/2022 |
6-K
| Quarterly results |
| 10/27/2022 |
6-K
| Quarterly results |
| 10/04/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 09/30/2022 |
6-K
| Quarterly results |
| 09/16/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 09/12/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 09/12/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"Notice of Annual General Meeting",
"Annual General Meeting of Trinity Biotech plc The board of directors of the Company encloses notice of an annual general meeting of the Company, to be held at the Company’s registered office at IDA Business Park, Bray, Co. Wicklow, Ireland, A98 H5C8, on September 30, 2022 at 10:00am . Business of Annual General Meeting We would like to take this opportunity to provide some additional information in relation to the various items of business which are to be considered at the AGM. Ordinary Business Resolution 1 seeks the approval from shareholders for an increase in the Company’s authorised share capital by the creation of an additional 600,000,000 A ordinary shares of US$0.0109 each, in order to maintain flexibility. Resolution 2 deals with the reappointment of Grant Thornton as statutory au...",
"Notice of Annual General Meeting",
"Annual General Meeting" |
|
| 07/01/2022 |
6-K
| Quarterly results |
| 05/23/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 05/09/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 04/11/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"6-K",
"DUBLIN, Ireland ..... Trinity Biotech plc , a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2021 and fiscal year 2021. Fiscal Year 2021 Results Total revenues for fiscal year 2021 were $93.0m compared to $102.0m in 2020, a decrease of 8.8% year on year and were broken down as follows: Full Year 2020 Full Year 2021 Increase/ US$’000 US$’000 % Point-of-Care 9,215 10,337 12.2% Clinical Laboratory 92,765 82,628 Total 101,980 92,965 Point-of-Care revenues increased from $9.2m in 2020 to $10.3m in 2021, which represents an increase of 12.2%. This was driven by higher HIV sales in Africa. In 2020, HIV revenues were negatively impacted by logistical and testing constraints ..." |
|
| 04/11/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 02/11/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 01/28/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 01/25/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 01/06/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 12/23/2021 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 12/23/2021 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
|
|
|